Vigene Biosciences is a gene therapy CDMO acquired by Charles River Laboratories for up to $350M to enhance gene therapy capabilities. The company specializes in AAV viral vector manufacturing. Website content was blocked (Cloudflare), but search results confirm the company engages in producing AAV vectors for gene therapy programs. Now operates as part of Charles River's cell and gene therapy platform.
AAV viral vector manufacturing, gene therapy CDMO services
1 site worldwide
No reviews available yet.
No documents available.